AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02465892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillars4Life
Description: The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
Study NCT04402892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )
Description: Patients hospitalized for CoV-2-SARS will be sampled at inclusion (Day 0), at day 21, at 3 months and at 6 months .
Study NCT04402892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)
Description: Patients who have recovered from CoV-2-SARS will be sampled at inclusion (Day 0), at 3 months and at 6 months .
Study NCT01211262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of participants will be treated at the RP2D or MTD.
Study NCT00989430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment
Description: Wearing prism goggles and performing visuomotor tasks during therapy sessions.
Study NCT04166045 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment Location
Description: The device applies transcutaneous electrical nerve stimulation to the bicep
Study NCT04166045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Verum Treatment Location
Description: The device applies transcutaneous electrical nerve stimulation to the hand
Study NCT00187707 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin
Description: Subjects will take a single dose of 400 mg of gabapentin
Study NCT01417780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AB103
Description: AB103 0.25 mg/kg or 0.5 mg/kg administered as a single IV infusion
Study NCT00759616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford Partial Knee
Description: Oxford Partial Knee
Study NCT01465191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
Study NCT03396354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated robotic surgery
Description: Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
Study NCT03396354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic surgery
Description: conventional laparoscopic gastrectomy will be performed.
Study NCT02161263 — intervention group
Intervention type: OTHER
Intervention: Patient Quality of Life andVision after LASIK Surgery
Description: Patient questionnaire
Study NCT03122522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab 3mg/kg
Study NCT03122522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab 1mg/kg
Study NCT00628628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: As Needed Rasburicase
Description: .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
Study NCT00628628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Rasburicase
Description: .15 mg/kg IV Over 30 Minutes Daily
Study NCT02839681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Administered intravenously (IV) every 3 weeks
Study NCT02839681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Research blood test for eligibility
Study NCT01656759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evicel Fibrin Spray
Description: 10cc syringe dose, once at the end of TKA
Study NCT03515304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: 420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Study NCT02667691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SODB Dimpless
Description: Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
Study NCT02667691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
Study NCT02667691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: caloric restriction
Description: Caloric recommendation reduced by 20%
Study NCT02667691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caloric restriction
Description: Caloric recommendation reduced by 20%
Study NCT01417780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride) administered as a single IV infusion
Study NCT03515304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Study NCT00493116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a
Description: dosage and frequency as per Biogen Idec protocol
Study NCT00493116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: dosage and frequency as per Biogen Idec protocol
Study NCT03586843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
Study NCT01198392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s-1 plus cisplatin
Description: S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01198392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fu plus cisplatin
Description: 5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03819088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Given PO
Study NCT01533038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift System
Description: The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study NCT01533038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate
Description: Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
Study NCT00493883 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: yttrium Y 90 microspheres (TheraSphere®)
Description: Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
Study NCT03230175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX01
Description: TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
Study NCT03230175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection and debridement
Description: Perform surgical sharp debridement in the OR, to remove:~* infectious agents and biofilms (purulence),~* all debris, eschar, callus and macerated non-viable tissue from the wound base, and~* dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge.~Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate.
Study NCT03230175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics
Description: Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
Study NCT03230175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Off-loading
Description: Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
Study NCT02409420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy informed by Acceptance and Commitment Therapy
Description: PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
Study NCT01437631 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic clip application
Description: prophylactic clip application after colonoscopic polypectomy
Study NCT03752853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based intervention for mild to moderate depression
Description: The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
Study NCT00379353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 100 mg capsules orally, once a day for 14 days.
Study NCT00379353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules orally, once a day for 14 days.
Study NCT01151280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WallFlex Biliary Fully Covered Stent
Description: Investigational device evaluated for the treatment for benign biliary strictures
Study NCT04783337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-pQCT (high resolution computertomograph)
Description: In addition to determining the bone density, a quantitative bone structure analysis with measurement of the number of thickness and distribution of the trabeculae can also be carried out. In addition, the finite element analysis (FEA) allows strength models of the examined bone to be created from the data of the hr-pqCTs. In this way, the osseous consolidation of the fracture can not only be observed, but also tested for resilience with the help of mathematical models.
Study NCT04338945 — intervention group
Intervention type: BEHAVIORAL
Intervention: COVID-surgRES questionaire
Description: The questionaire gives a multidimensional assessment of residents' impression with regard to impact of COVID emergency on Italian specialist training programs
Study NCT00110383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-Based Supervised Asthma Therapy
Description: Child's inhaled steroid use supervised daily at school
Study NCT01723501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine
Description: 0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
Study NCT04783337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood withdrawal
Description: Bone remodeling blood marker: S-CTX (Crosslaps), S-TRA5b ( tartrate-resistant acid phosphatase), S-PINP (Procollagen type 1 amino-terminal propeptide), BALP, Calcium, parathyroid hormone, 25-OH-Vitamin D3 (HPLC)
Study NCT01610050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFA102
Study NCT02083809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous oxytocin
Description: 30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
Study NCT02083809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Fluids and Electrolytes
Description: 500 ml of inert IV fluid
Study NCT02607839 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: glucose or normal saline
Description: 20% glucose solution or normal saline, intravenous infusion
Study NCT02607839 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: glucose or normal saline
Description: 20% glucose solution or normal saline, intravenous infusion
Study NCT00558779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OBCAB (Off Pump Coronary Artery Bypass Grafting)
Description: OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
Study NCT00558779 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG (coronary artery bypass grafting)
Description: conventional CABG with cardiopulmonary bypass
Study NCT03764488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.
Study NCT03764488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MAG3-BIIB067
Description: Administered as specified in the treatment arm.
Study NCT01171664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, one BID
Study NCT01171664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAHIST
Description: STAHIST in tablet form dosed one BID
Study NCT01205178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
Study NCT01205178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
Study NCT01205178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafenoquine
Description: Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
Study NCT05438641 — intervention group
Intervention type: DRUG
Intervention: BZDP-Sparing Protocol
Description: BZDP-Sparing group includes subjects primarily treated with a non-BZDP agent (e.g., Alpha-2 agonists and/or anticonvulsants). Rescue with BZDP-based treatment allowed if there is symptomatic breakthrough- as measured by CIWA > 15.
Study NCT05438641 — intervention group
Intervention type: DRUG
Intervention: BZDP-Based Protocol
Description: Patients in this arm will received active treatment based on conventional BZDP-based protocol; additional BZDP are permitted for patients who are still symptomatic, based on CIWA-Protocol.
Study NCT01025765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
Study NCT01025765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg).
Study NCT01025765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; \< 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
Study NCT02034071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCCR
Study NCT02034071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04632914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk stabilizing exercise
Description: trunk stabilizing exercise is a group of exercise which train the anterior thoracic cage and abdominal muscles in the form of static contraction of these muscles from a different position supine, sitting and standing.
Study NCT04632914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac rehabilitation programe
Description: all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
Study NCT04632914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation programe
Description: all patients continue this routine physiotherapy program for 40-60min.the patients incorporated into a variety of exercises conducted through arm ergometer,leg ergometer and treadmill.also the patients perform deep breathing exercise and coughing ececise
Study NCT03128151 — intervention group
Intervention type: BEHAVIORAL
Intervention: Educational program for clinicians: implementation of a package of clinical prevention measures of NMB
Description: Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
Study NCT01411072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
Study NCT01411072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
Study NCT02028871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Insulin
Study NCT02028871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00602745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: oral administration
Study NCT00602745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: intravenous bolus
Study NCT01889160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4721 Solution
Description: 1-9 mg/mL liquid solution
Study NCT01889160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4721 Placebo
Description: Liquid solution
Study NCT01889160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4721 Suspension
Description: 9 mg/g liquid suspension
Study NCT00915070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BQ-123
Description: 60 mcg/min, infusion period: 60 min
Study NCT00915070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BQ-123
Description: 60 mcg/min, infusion period: 60 min
Study NCT00915070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiological saline solution
Description: infusion period 60 minutes
Study NCT01723501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: Sterile water wipes (placebo)
Study NCT01353833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.